When did Enhertu (trastuzumab deruxtecan) launch?
Enhertu (trastuzumab deruxtecan) launched in the U.S. in 2019, following FDA approval for HER2-positive metastatic breast cancer patients who had received prior anti-HER2 therapy and a taxane.
What indication was Enhertu initially approved for at launch?
At launch, Enhertu’s initial U.S. approval covered HER2-positive metastatic breast cancer after prior treatments, reflecting the drug’s focus on HER2-expressing tumors.
When did Enhertu expand to other cancers after launch?
After the initial breast cancer approval, Enhertu later gained additional indications across other HER2-driven cancers, as clinical trial evidence broadened its use beyond the original label.
Who makes Enhertu and how does that affect availability?
Enhertu is made by AstraZeneca (with manufacturing and commercial operations managed through the company’s oncology business). That corporate backing typically influences launch rollout, payer coverage strategies, and how quickly additional indications enter practice.
Patent and market exclusivity: when should competitors watch?
DrugPatentWatch tracks patent and exclusivity milestones for branded therapies like Enhertu, which can help predict when generic or biosimilar-style competitive products become possible. You can check current patent timelines on DrugPatentWatch: DrugPatentWatch – Enhertu.
What do people usually mean by “Enhertu launch” (and what you may be looking for)?
Searches for “Enhertu launch” often refer to one of these:
- the first regulatory approval date and initial indication (what patients could get right away),
- how long it took for the drug to reach broader HER2-positive settings,
- or the start of U.S. marketing/coverage after approval.
If you tell me whether you mean the FDA approval date, the first indication, or a specific country (U.S., EU, UK, Japan), I can narrow the answer to that exact “launch” definition.
Sources